Prospective Comparison of Surgery Outcome Between Preoperative and Intraoperative Intravitreal Injection of Ranibizumab for Vitrectomy in Proliferative Diabetic Retinopathy Patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2193-6528
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Prospective Comparison of Surgery Outcome Between Preoperative and Intraoperative Intravitreal Injection of Ranibizumab for Vitrectomy in Proliferative Diabetic Retinopathy Patients ; volume:11 ; number:5 ; day:29 ; month:7 ; year:2022 ; pages:1833-1845 ; date:10.2022
Ophthalmology and therapy ; 11, Heft 5 (29.7.2022), 1833-1845, 10.2022
- Creator
-
Li, Siying
Tang, Jiyang
Han, Xinyao
Wang, Zongyi
Zhang, Linqi
Zhao, Mingwei
Qu, Jinfeng
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40123-022-00550-7
- URN
-
urn:nbn:de:101:1-2022111909304153632139
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Li, Siying
- Tang, Jiyang
- Han, Xinyao
- Wang, Zongyi
- Zhang, Linqi
- Zhao, Mingwei
- Qu, Jinfeng
- SpringerLink (Online service)
Other Objects (12)
Refining vitrectomy for proliferative diabetic retinopathy
The efficacy and safety of intravitreal injection of Ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage
Comparison of efficacy and safety of intravitreal ranibizumab and conbercept before vitrectomy in Chinese proliferative diabetic retinopathy patients: a prospective randomized controlled trial
Post-vitrectomy delayed retinal breaks in proliferative diabetic retinopathy
Ranibizumab Pretreatment in Vitrectomy with Internal Limiting Membrane Peeling on Diabetic Macular Edema in Severe Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity
Ghost cell glaucoma after intravitreous injection of ranibizumab in proliferative diabetic retinopathy
Effect of intravitreal or sub-tenon triamcinolone acetonide injection at completion of vitrectomy on peripheral retinochoroidal thickness in eyes with proliferative diabetic retinopathy
Intravitreal bevacizumab (IVB) versus IVB in combination with pars plana vitrectomy for vitreous hemorrhage secondary to proliferative diabetic retinopathy: a randomized clinical trial
Characteristics and outcomes of vitrectomy for proliferative diabetic retinopathy in young versus senior patients
Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease
The effect of adjunctive intravitreal conbercept at the end of diabetic vitrectomy for the prevention of post-vitrectomy hemorrhage in patients with severe proliferative diabetic retinopathy: a prospective, randomized pilot study
Refining vitrectomy for proliferative diabetic retinopathy
The efficacy and safety of intravitreal injection of Ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage
Comparison of efficacy and safety of intravitreal ranibizumab and conbercept before vitrectomy in Chinese proliferative diabetic retinopathy patients: a prospective randomized controlled trial
Post-vitrectomy delayed retinal breaks in proliferative diabetic retinopathy
Ranibizumab Pretreatment in Vitrectomy with Internal Limiting Membrane Peeling on Diabetic Macular Edema in Severe Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity
Ghost cell glaucoma after intravitreous injection of ranibizumab in proliferative diabetic retinopathy
Effect of intravitreal or sub-tenon triamcinolone acetonide injection at completion of vitrectomy on peripheral retinochoroidal thickness in eyes with proliferative diabetic retinopathy
Intravitreal bevacizumab (IVB) versus IVB in combination with pars plana vitrectomy for vitreous hemorrhage secondary to proliferative diabetic retinopathy: a randomized clinical trial
Characteristics and outcomes of vitrectomy for proliferative diabetic retinopathy in young versus senior patients
Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease
The effect of adjunctive intravitreal conbercept at the end of diabetic vitrectomy for the prevention of post-vitrectomy hemorrhage in patients with severe proliferative diabetic retinopathy: a prospective, randomized pilot study
Refining vitrectomy for proliferative diabetic retinopathy
The efficacy and safety of intravitreal injection of Ranibizumab as pre-treatment for vitrectomy in proliferative diabetic retinopathy with vitreous hemorrhage
Comparison of efficacy and safety of intravitreal ranibizumab and conbercept before vitrectomy in Chinese proliferative diabetic retinopathy patients: a prospective randomized controlled trial
Post-vitrectomy delayed retinal breaks in proliferative diabetic retinopathy
Ranibizumab Pretreatment in Vitrectomy with Internal Limiting Membrane Peeling on Diabetic Macular Edema in Severe Proliferative Diabetic Retinopathy
Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity
Ghost cell glaucoma after intravitreous injection of ranibizumab in proliferative diabetic retinopathy
Effect of intravitreal or sub-tenon triamcinolone acetonide injection at completion of vitrectomy on peripheral retinochoroidal thickness in eyes with proliferative diabetic retinopathy
Intravitreal bevacizumab (IVB) versus IVB in combination with pars plana vitrectomy for vitreous hemorrhage secondary to proliferative diabetic retinopathy: a randomized clinical trial
Characteristics and outcomes of vitrectomy for proliferative diabetic retinopathy in young versus senior patients
Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease